Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in $2.13 billion deal
MRK•Merck signed an exclusive global license with SciBrunch Therapeutics for preclinical oral KRAS G12D inhibitor SPR2015, paying $400 million upfront. Milestones could bring the deal’s total value to $2.13 billion, and Merck expects a $400 million pre-tax charge in Q3 2026, about $0.13 per share.
1. License deal terms
Merck signed an exclusive global license with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor, gaining worldwide rights to develop, manufacture and commercialize the drug. SciBrunch will receive $400 million upfront, with milestone payments potentially bringing the deal’s value to $2.13 billion across multiple indications; Merck expects a $400 million pre-tax charge in Q3 2026, about $0.13 per share.
